Introduction: The prudent utilization of antibiotics has resulted in the rise of multidrug resistance within Enterobacterales, mainly attributable to the production of beta-lactamases like Carbapenemases. Combination therapy, particularly Ceftazidime-Avibactam (CZA), has emerged as a preferred strategy. Resistance to this combination has also been noted, prompting this investigation to evaluate CZA's in vitro susceptibility against multidrug-resistant pathogens. Objectives: 1. To isolate and identify CRE from various clinical samples 2. To assess CZA's in vitro susceptibility to these CRE isolates. Material & methods: In the course of a six-month observational research, all samples obtained at the microbiology lab, were examined. Identification of Enterobacterales was carried out using standard techniques. CRE strains were identified by conventional Mcim and microbroth dilution methods through the Vitek-2 system. Testing for CZA in CRE strains was conducted using the Kirby Bauer disc diffusion method as well as MIC determination with the Vitek-2 system. Results: In a sample set of 45 specimens, 33% and 67%, respectively, of the detected CRE isolates were Klebsiella pneumoniae&Escherichia coli. Among the E. Coli isolates, 29% (13) exhibited susceptibility to CZA, while 38% (17) showed resistance to CZA. Regarding Klebsiella pneumoniae, 13% (6) were susceptible to CZA, whereas 20% (9) displayed resistance to CZA. Conclusion: The IDSA (Infectious Diseases Society of America) states that the CZA is a preferred single-drug therapy for curing infections caused by CRE. However, a rise of resistance to CZA is a growing concern, leading to the need for careful monitoring to improve its effectiveness.